Enalapril
Enalapril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for VASOTEC tablets (enalapril maleate), lists three uses: treating high blood pressure, treating symptomatic congestive heart failure (usually together with diuretics and digitalis), and slowing the development of overt heart failure in clinically stable people who have no symptoms but have a reduced left ventricular ejection fraction (35 percent or less). Vasotec is the brand name on the label read.
Also called Vasotec · Enalapril maleate
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 3827; UNII 9O25354EPJ. The label names the substance as enalapril maleate, so UNII 9O25354EPJ is the UNII of the maleate salt and is a broad match. MeSH descriptor D004656 is Enalapril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Bausch Health US LLC label for VASOTEC (enalapril maleate) tablets, application NDA018998, effective 2026-01-23 in openFDA; Drugs@FDA lists the application's sponsor as BAUSCH. Other enalapril labels, including the Epaned oral solution label, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 15 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 15
- Phase 3 or 4
- 13
- Recruiting
- 0
- Regulatory decisions
- 0
| Phase | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 1/2 | 0 | 0 | 1 | 1 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 3 | 1 | 2 | 6 |
| Phase 4 | 5 | 0 | 2 | 7 |
| All phases | 9 | 1 | 5 | 15 |
Conditions these trials study
- Heart failure
- Heart failure with reduced ejection fraction (HFrEF)
- Hypertension (high blood pressure)
- Cardiomyopathy (heart muscle disease)
- Chronic kidney disease (CKD)
- Heart attack (myocardial infarction)
- Heart failure with mildly reduced or preserved ejection fraction
- ST-elevation heart attack (STEMI)
Sponsors with the most trials
- Novartis
- Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań
- Ministry of Health, Sri Lanka
- RECORDATI GROUP
- Shenzhen Ausa Pharmed Co.,Ltd
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
9O25354EPJ
Claims and evidence
Context Patients for whom the US label of enalapril (Vasotec) lists an indication: hypertension, symptomatic congestive heart failure, asymptomatic left ventricular dysfunction with ejection fraction 35 percent or less
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients with hypertension
- Patients with symptomatic congestive heart failure
- Clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction 35 percent or less)
- Excluded
- None stated
The US label of VASOTEC (enalapril maleate) tablets, in the Bausch Health US LLC version dated 2026-01-23 in openFDA, lists the medicine for the treatment of hypertension; for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis; and, in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction 35 percent or less), to decrease the rate of development of overt heart failure.
Applies to Recipient not specified Patients for whom the US label of enalapril (Vasotec) lists an indication: hypertension, symptomatic congestive heart failure, asymptomatic left ventricular dysfunction with ejection fraction 35 percent or less
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-01-23
- Source state
- Current
- Version fingerprint
5f863c2bf22396afec6b5c4ca54d79c10d17deea45b25bc7f69704b4ea0109a8- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260123.
- Retrieved
- Source effective date
- 2026-01-23
- Source state
- Current
- Version fingerprint
5f863c2bf22396afec6b5c4ca54d79c10d17deea45b25bc7f69704b4ea0109a8- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Background openFDA Drugs@FDA record for application NDA018998 (VASOTEC, sponsor BAUSCH): product and sponsor
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application NDA018998, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
416a5458130c571132ec7563ce9664a1d19380b14779e933909278478bb7dad2- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
EPANED
No label from the application holder was found in the openFDA label dataset for application NDA208686. This page does not show another labeler's label in its place.
EPANED KIT
No label from the application holder was found in the openFDA label dataset for application NDA204308. This page does not show another labeler's label in its place.
LEXXEL
No label from the application holder was found in the openFDA label dataset for application NDA020668. This page does not show another labeler's label in its place.
TECZEM
No label from the application holder was found in the openFDA label dataset for application NDA020507. This page does not show another labeler's label in its place.
VASERETIC
No label from the application holder was found in the openFDA label dataset for application NDA019221. This page does not show another labeler's label in its place.
VASOTEC
No label from the application holder was found in the openFDA label dataset for application NDA018998. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA018998 - Approval
NDA019221 - Supplemental approval
NDA018998 - Supplemental approval
NDA018998 - Supplemental approval
NDA018998 - Supplemental approval
NDA018998 - Supplemental approval
NDA019221 - Approval
NDA020507 - Approval
NDA020668 - Supplemental approval
NDA018998 - Approval
NDA204308 - Supplemental approval
NDA204308 - Supplemental approval
NDA204308 - Approval
NDA208686
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
Applies to Recipient not specified Patients for whom the US label of enalapril (Vasotec) lists an indication: hypertension, symptomatic congestive heart failure, asymptomatic left ventricular dysfunction with ejection fraction 35 percent or less
The US label of VASOTEC (enalapril maleate) tablets, in the Bausch Health US LLC version dated 2026-01-23 in openFDA, lists the medicine for the treatment of hypertension; for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis; and, in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction 35 percent or less), to decrease the rate of development of overt heart failure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists symptomatic congestive heart failure, and slowing the development of overt heart failure in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction 35 percent or less), as indications: Heart failure
Applies to Recipient not specified Patients for whom the US label of enalapril (Vasotec) lists an indication: hypertension, symptomatic congestive heart failure, asymptomatic left ventricular dysfunction with ejection fraction 35 percent or less
The US label of VASOTEC (enalapril maleate) tablets, in the Bausch Health US LLC version dated 2026-01-23 in openFDA, lists the medicine for the treatment of hypertension; for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis; and, in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction 35 percent or less), to decrease the rate of development of overt heart failure.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 6
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 5 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 14
Record details
- Record id
cardio:enalapril- Content hash
b560f1dde21772e71b0f6957bea5d4e40bb8f477be23a6a624d2f814084b34b8